RFA
NKTR icon

Reilly Financial Advisors’s Nektar Therapeutics NKTR Stock Holding History

Reilly Financial Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-26
Closed -$13K – 993
2019
Q1 		$13K Hold
26
– – ﹤0.01% 619
2018
Q4 		$13K Hold
26
– – ﹤0.01% 591
2018
Q3 		$24K Buy
+26
New +$22.2K ﹤0.01% 513

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Reilly Financial Advisors's NKTR Position: Q2 2019 in Review

Reilly Financial Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 26 shares — an estimated $13K sold.

Reilly Financial Advisors first reported a position in NKTR in Q3 2018 and held it in 3 quarters. The position peaked at $24K in Q3 2018. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

  • Reilly Financial Advisors reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Reilly Financial Advisors sold 26 Nektar Therapeutics shares in Q2 2019, an estimated $13K.
  • Reilly Financial Advisors first reported a position in Nektar Therapeutics in Q3 2018 and held it in 3 quarters.
  • Reilly Financial Advisors's Nektar Therapeutics position peaked at $24K in Q3 2018.
  • 336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on Reilly Financial Advisors's 13F filing for Q2 2019, filed 23 Jul 2019.